{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,8]],"date-time":"2025-07-08T04:11:11Z","timestamp":1751947871069,"version":"3.41.2"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,7,7]]},"DOI":"10.7759\/cureus.87447","type":"journal-article","created":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T15:36:01Z","timestamp":1751902561000},"source":"Crossref","is-referenced-by-count":0,"title":["Effectiveness and Safety of Switching to Fixed-Dose, Preservative-Free Tafluprost\/Timolol in the Treatment of Open-Angle Glaucoma or Ocular Hypertension: A Real-World Study in Taiwan"],"prefix":"10.7759","author":[{"given":"Wei-Wen","family":"Su","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yung-Sung","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","article-title":"Glaucoma","volume":"93","author":"Gupta D","year":"2016","unstructured":"Gupta D, Chen PP. Glaucoma. Am Fam Physician. 2016, 93:668-74.","journal-title":"Am Fam Physician"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2014.3192","article-title":"The pathophysiology and treatment of glaucoma: a review","volume":"311","author":"Weinreb RN","year":"2014","unstructured":"Weinreb RN, Aung T, Medeiros FA. The pathophysiology and treatment of glaucoma: a review. JAMA. 2014, 311:1901-11. 10.1001\/jama.2014.3192","journal-title":"JAMA"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/S2214-109X(20)30489-7","article-title":"Causes of blindness and vision impairment in 2020 and trends over 30 years, and prevalence of avoidable blindness in relation to VISION 2020: the Right to Sight: an analysis for the Global Burden of Disease Study","volume":"9","year":"2021","unstructured":"Causes of blindness and vision impairment in 2020 and trends over 30 years, and prevalence of avoidable blindness in relation to VISION 2020. the Right to Sight: an analysis for the Global Burden of Disease Study. Lancet Glob Health. 2021, 9:e144-60. 10.1016\/S2214-109X(20)30489-7","journal-title":"Lancet Glob Health"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-92971-w","article-title":"Prevalence of primary open angle glaucoma in the last 20 years: a meta-analysis and systematic review","volume":"11","author":"Zhang N","year":"2021","unstructured":"Zhang N, Wang J, Li Y, Jiang B. Prevalence of primary open angle glaucoma in the last 20 years: a meta-analysis and systematic review. Sci Rep. 2021, 11:13762. 10.1038\/s41598-021-92971-w","journal-title":"Sci Rep"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1097\/JCMA.0000000000000385","article-title":"Prevalence of glaucoma in the elderly population in Taiwan: the Shihpai Eye Study","volume":"83","author":"Kuo CY","year":"2020","unstructured":"Kuo CY, Ko YC, Kuang TM, Chou P, Chiou SH, Liu CJ. Prevalence of glaucoma in the elderly population in Taiwan: the Shihpai Eye Study. J Chin Med Assoc. 2020, 83:880-4. 10.1097\/JCMA.0000000000000385","journal-title":"J Chin Med Assoc"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1007\/s10384-022-00970-9","article-title":"The Japan Glaucoma Society guidelines for glaucoma 5th edition","volume":"67","author":"Kiuchi Y","year":"2023","unstructured":"Kiuchi Y, Inoue T, Shoji N, Nakamura M, Tanito M. The Japan Glaucoma Society guidelines for glaucoma 5th edition. Jpn J Ophthalmol. 2023, 67:189-254. 10.1007\/s10384-022-00970-9","journal-title":"Jpn J Ophthalmol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-021-01725-7","article-title":"Treatment of open-angle glaucoma and ocular hypertension with preservative-free tafluprost\/timolol fixed-dose combination therapy: UK and Ireland results from the VISIONARY Study","volume":"38","author":"Ansari E","year":"2021","unstructured":"Ansari E, Pavicic-Astalos J, Ayan F, King AJ, Kinsella M, Ng E, Nita A. Treatment of open-angle glaucoma and ocular hypertension with preservative-free tafluprost\/timolol fixed-dose combination therapy: UK and Ireland results from the VISIONARY Study. Adv Ther. 2021, 38:2990-3002. 10.1007\/s12325-021-01725-7","journal-title":"Adv Ther"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1080\/17425255.2016.1209481","article-title":"Ocular surface toxicity from glaucoma topical medications and associated preservatives such as benzalkonium chloride (BAK)","volume":"12","author":"Aguayo Bonniard A","year":"2016","unstructured":"Aguayo Bonniard A, Yeung JY, Chan CC, Birt CM. Ocular surface toxicity from glaucoma topical medications and associated preservatives such as benzalkonium chloride (BAK). Expert Opin Drug Metab Toxicol. 2016, 12:1279-89. 10.1080\/17425255.2016.1209481","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2022.2135701","article-title":"Reviewing the evidence surrounding preservative-free tafluprost\/timolol fixed-dose combination therapy in open-angle glaucoma and ocular hypertension management: a focus on efficacy, safety, and tolerability","volume":"21","author":"Oddone F","year":"2022","unstructured":"Oddone F. Reviewing the evidence surrounding preservative-free tafluprost\/timolol fixed-dose combination therapy in open-angle glaucoma and ocular hypertension management: a focus on efficacy, safety, and tolerability. Expert Opin Drug Saf. 2022, 21:1259-68. 10.1080\/14740338.2022.2135701","journal-title":"Expert Opin Drug Saf"},{"key":"ref10","unstructured":"Survey on available preservative-free fixed-dose combination in Taiwan (2023). https.\/\/info.fda.gov.tw\/MLMS\/H0001.aspx."},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1089\/jop.2021.0099","article-title":"Treatment of open-angle glaucoma and ocular hypertension with preservative-free tafluprost\/timolol fixed-dose combination therapy: results from the VISIONARY study population in Spain","volume":"38","author":"Garcia-Medina JJ","year":"2022","unstructured":"Garcia-Medina JJ, Benitez-Del-Castillo J, Rodr\u00edguez-Agirretxe I, Lopez-Lopez F, Moreno-Valladares A. Treatment of open-angle glaucoma and ocular hypertension with preservative-free tafluprost\/timolol fixed-dose combination therapy: results from the VISIONARY study population in Spain. J Ocul Pharmacol Ther. 2022, 38:252-60. 10.1089\/jop.2021.0099","journal-title":"J Ocul Pharmacol Ther"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-022-02166-6","article-title":"Switching to preservative-free tafluprost\/timolol fixed-dose combination in the treatment of open-angle glaucoma or ocular hypertension: subanalysis of data from the VISIONARY study according to baseline monotherapy treatment","volume":"39","author":"Oddone F","year":"2022","unstructured":"Oddone F, Kirwan J, Lopez-Lopez F, Zimina M, Fassari C, Holl\u00f3 G. Switching to preservative-free tafluprost\/timolol fixed-dose combination in the treatment of open-angle glaucoma or ocular hypertension: subanalysis of data from the VISIONARY study according to baseline monotherapy treatment. Adv Ther. 2022, 39:3501-21. 10.1007\/s12325-022-02166-6","journal-title":"Adv Ther"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S364880","article-title":"Treatment of open-angle glaucoma and ocular hypertension with the fixed-dose combination of preservative-free tafluprost\/timolol: clinical outcomes from ophthalmology clinics in Italy","volume":"16","author":"Oddone F","year":"2022","unstructured":"Oddone F, Scorcia V, Iester M, et al.. Treatment of open-angle glaucoma and ocular hypertension with the fixed-dose combination of preservative-free tafluprost\/timolol: clinical outcomes from ophthalmology clinics in Italy. Clin Ophthalmol. 2022, 16:1707-19. 10.2147\/OPTH.S364880","journal-title":"Clin Ophthalmol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-020-01239-8","article-title":"Treatment of open-angle glaucoma and ocular hypertension with preservative-free tafluprost\/timolol fixed-dose combination therapy: the VISIONARY study","volume":"37","author":"Oddone F","year":"2020","unstructured":"Oddone F, Tanga L, K\u00f3thy P, Holl\u00f3 G. Treatment of open-angle glaucoma and ocular hypertension with preservative-free tafluprost\/timolol fixed-dose combination therapy: the VISIONARY study. Adv Ther. 2020, 37:1436-51. 10.1007\/s12325-020-01239-8","journal-title":"Adv Ther"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S128453","article-title":"Preservative-free fixed combination of tafluprost 0.0015% and timolol 0.5% in patients with open-angle glaucoma and ocular hypertension: results of an open-label observational study","volume":"11","author":"Pillunat LE","year":"2017","unstructured":"Pillunat LE, Erb C, Ropo A, Kimmich F, Pfeiffer N. Preservative-free fixed combination of tafluprost 0.0015% and timolol 0.5% in patients with open-angle glaucoma and ocular hypertension: results of an open-label observational study. Clin Ophthalmol. 2017, 11:1051-64. 10.2147\/OPTH.S128453","journal-title":"Clin Ophthalmol"},{"key":"ref16","unstructured":"Tapcom-S full prescribing information. https.\/\/www.mims.com\/singapore\/drug\/info\/tapcom-s."},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.alit.2016.12.004","article-title":"Japanese guidelines for allergic conjunctival diseases 2017","volume":"66","author":"Takamura E","year":"2017","unstructured":"Takamura E, Uchio E, Ebihara N, et al.. Japanese guidelines for allergic conjunctival diseases 2017. Allergol Int. 2017, 66:220-9. 10.1016\/j.alit.2016.12.004","journal-title":"Allergol Int"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-014-0151-7","article-title":"Fixed-dose combination of tafluprost and timolol in the treatment of open-angle glaucoma and ocular hypertension: comparison with other fixed-combination products","volume":"31","author":"Holl\u00f3 G","year":"2014","unstructured":"Holl\u00f3 G, Vuorinen J, Tuominen J, Huttunen T, Ropo A, Pfeiffer N. Fixed-dose combination of tafluprost and timolol in the treatment of open-angle glaucoma and ocular hypertension: comparison with other fixed-combination products. Adv Ther. 2014, 31:932-44. 10.1007\/s12325-014-0151-7","journal-title":"Adv Ther"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtos.2017.05.008","article-title":"TFOS DEWS II definition and classification report","volume":"15","author":"Craig JP","year":"2017","unstructured":"Craig JP, Nichols KK, Akpek EK, et al.. TFOS DEWS II definition and classification report. Ocul Surf. 2017, 15:276-83. 10.1016\/j.jtos.2017.05.008","journal-title":"Ocul Surf"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2022.2083324","article-title":"A comparison of country-level data from the VISIONARY study examining treatment outcomes with preservative-free tafluprost\/timolol fixed-dose combination therapy","volume":"38","author":"Holl\u00f3 G","year":"2022","unstructured":"Holl\u00f3 G, Kirwan J, Lopez-Lopez F, Zimina M, Fassari C, Oddone F. A comparison of country-level data from the VISIONARY study examining treatment outcomes with preservative-free tafluprost\/timolol fixed-dose combination therapy. Curr Med Res Opin. 2022, 38:1189-201. 10.1080\/03007995.2022.2083324","journal-title":"Curr Med Res Opin"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1111\/j.1755-3768.2008.01380.x","article-title":"Pharmacokinetics, efficacy and safety profiles of preserved and preservative-free tafluprost in healthy volunteers","volume":"242","author":"Uusitalo H","year":"2008","unstructured":"Uusitalo H, Kaarniranta K, Ropo A. Pharmacokinetics, efficacy and safety profiles of preserved and preservative-free tafluprost in healthy volunteers. Acta Ophthalmol Suppl (Oxf ). 2008, 242:7-13. 10.1111\/j.1755-3768.2008.01380.x","journal-title":"Acta Ophthalmol Suppl (Oxf )"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.2147\/opth.s10441","article-title":"Clinical utility and differential effects of prostaglandin analogs in the management of raised intraocular pressure and ocular hypertension","volume":"4","author":"Lee AJ","year":"2010","unstructured":"Lee AJ, McCluskey P. Clinical utility and differential effects of prostaglandin analogs in the management of raised intraocular pressure and ocular hypertension. Clin Ophthalmol. 2010, 4:741-64. 10.2147\/opth.s10441","journal-title":"Clin Ophthalmol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1111\/cod.14245","article-title":"Topical eye medications causing allergic contact dermatitis","volume":"88","author":"Ahlstr\u00f6m MG","year":"2023","unstructured":"Ahlstr\u00f6m MG, Skov L, Heegaard S, Zachariae C, Garvey LH, Johansen JD. Topical eye medications causing allergic contact dermatitis. Contact Dermatitis. 2023, 88:294-9. 10.1111\/cod.14245","journal-title":"Contact Dermatitis"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-0162","article-title":"Allergic contact dermatitis due to beta-blockers in eye drops: a retrospective analysis of multicentre surveillance data 1993-2004","volume":"86","author":"Jappe U","year":"2006","unstructured":"Jappe U, Uter W, Menezes de P\u00e1dua CA, Herbst RA, Schnuch A. Allergic contact dermatitis due to beta-blockers in eye drops: a retrospective analysis of multicentre surveillance data 1993-2004. Acta Derm Venereol. 2006, 86:509-14. 10.2340\/00015555-0162","journal-title":"Acta Derm Venereol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-014-0163-3","article-title":"A 6-month study comparing efficacy, safety, and tolerability of the preservative-free fixed combination of tafluprost 0.0015% and timolol 0.5% versus each of its individual preservative-free components","volume":"31","author":"Pfeiffer N","year":"2014","unstructured":"Pfeiffer N, Traverso CE, Lorenz K, et al.. A 6-month study comparing efficacy, safety, and tolerability of the preservative-free fixed combination of tafluprost 0.0015% and timolol 0.5% versus each of its individual preservative-free components. Adv Ther. 2014, 31:1228-46. 10.1007\/s12325-014-0163-3","journal-title":"Adv Ther"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.2174\/1874364101812010121","article-title":"Efficacy and safety of switching from tafluprost to a tafluprost\/timolol fixed combination in patients with primary open-angle glaucoma","volume":"12","author":"Inoue K","year":"2018","unstructured":"Inoue K, Ueda T, Ishida K, Tomita G. Efficacy and safety of switching from tafluprost to a tafluprost\/timolol fixed combination in patients with primary open-angle glaucoma. Open Ophthalmol J. 2018, 12:121-6. 10.2174\/1874364101812010121","journal-title":"Open Ophthalmol J"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/460483","article-title":"The effects of topical antiglaucoma drugs as monotherapy on the ocular surface: a prospective study","volume":"2014","author":"Aydin Kurna S","year":"2014","unstructured":"Aydin Kurna S, Acikgoz S, Altun A, Ozbay N, Sengor T, Olcaysu OO. The effects of topical antiglaucoma drugs as monotherapy on the ocular surface: a prospective study. J Ophthalmol. 2014, 2014:460483. 10.1155\/2014\/460483","journal-title":"J Ophthalmol"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1097\/OPX.0000000000000667","article-title":"Association between glaucoma medication usage and dry eye in Taiwan","volume":"92","author":"Chen HY","year":"2015","unstructured":"Chen HY, Lin CL, Tsai YY, Kao CH. Association between glaucoma medication usage and dry eye in Taiwan. Optom Vis Sci. 2015, 92:e227-32. 10.1097\/OPX.0000000000000667","journal-title":"Optom Vis Sci"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1089\/jop.2013.0229","article-title":"Efficacy, safety, and tolerability of preservative-free fixed combination of tafluprost 0.0015%\/timolol 0.5% versus concomitant use of the ingredients","volume":"30","author":"Holl\u00f3 G","year":"2014","unstructured":"Holl\u00f3 G, Hommer A, Ant\u00f3n L\u00f3pez A, Ropo A. Efficacy, safety, and tolerability of preservative-free fixed combination of tafluprost 0.0015%\/timolol 0.5% versus concomitant use of the ingredients. J Ocul Pharmacol Ther. 2014, 30:468-75. 10.1089\/jop.2013.0229","journal-title":"J Ocul Pharmacol Ther"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/311862-effectiveness-and-safety-of-switching-to-fixed-dose-preservative-free-tafluprosttimolol-in-the-treatment-of-open-angle-glaucoma-or-ocular-hypertension-a-real-world-study-in-taiwan","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T15:36:02Z","timestamp":1751902562000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/311862-effectiveness-and-safety-of-switching-to-fixed-dose-preservative-free-tafluprosttimolol-in-the-treatment-of-open-angle-glaucoma-or-ocular-hypertension-a-real-world-study-in-taiwan"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,7]]},"references-count":29,"URL":"https:\/\/doi.org\/10.7759\/cureus.87447","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7,7]]}}}